Orthobiologics

MagnetOs Granules and MagnetOs Putty received TGA approval in Australia. Initial market launch is scheduled for late 1Q21....

Tornado synthetic and bioactive bone graft alternative is delivered to the surgical site safely and quickly using the GraftMag Graft...

DUROLANE injection treats knee osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacological therapy or analgesics....

MagnetOs bone graft, an alternative to autograft, has experienced strong adoption by spinal surgeons since U.S. launch in 2019....

The research is investigating amniotic tissue as a potential treatment for chronic musculoskeletal pain and function disorders. ...

Canada will be the first commercial market to launch i-FACTOR+ Matrix. The technology is currently being studied in an FDA...

This U.S. Phase II trial intends to demonstrate safety and efficacy of Fibrin-PTH in patients undergoing a single-level TLIF procedure....

OsteoFlo NanoPutty bone graft features the world’s first quadphasic synthetic bone graft particles with nano-surface technology. ...

The company announced the U.S. commercial launch of the Matriform Si, a silicated synthetic bone graft substitute designed and cleared...

The IDE Supplement allows for a reduction in the number of patients required to be enrolled in the ASPIRE IDE...